Molecular subtypes and local-regional control of breast cancer

SM Fragomeni, A Sciallis… - Surgical Oncology …, 2018 - surgonc.theclinics.com
Breast cancer is a heterogeneous disease that affects one anatomic site, yet is
phenotypically variable. 1, 2 The identification of different biological subtypes occurs …

[HTML][HTML] BRCA1-and BRCA2-associated hereditary breast and ovarian cancer

N Petrucelli, MB Daly, T Pal - 2022 - europepmc.org
BRCA1-and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is
characterized by an increased risk for female and male breast cancer, ovarian cancer …

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

S Yadav, NJ Boddicker, J Na, EC Polley… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To estimate the risk of contralateral breast cancer (CBC) among women with
germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 …

Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

N Mavaddat, S Peock, D Frost, S Ellis… - JNCI: Journal of the …, 2013 - academic.oup.com
Background Reliable estimates of cancer risk are critical for guiding management of BRCA1
and BRCA2 mutation carriers. The aims of this study were to derive penetrance estimates for …

Racial disparities in BRCA testing and cancer risk management across a population‐based sample of young breast cancer survivors

D Cragun, A Weidner, C Lewis, D Bonner, J Kim… - Cancer, 2017 - Wiley Online Library
BACKGROUND Breast cancer (BC) disparities may widen with genomic advances. The
authors compared non‐Hispanic white (NHW), black, and Hispanic BC survivors for 1) …

Germline testing in patients with breast cancer: ASCO–Society of Surgical Oncology Guideline

I Bedrosian, MR Somerfield, MI Achatz… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE To develop recommendations for germline mutation testing for patients with
breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to …

Assessing the risk of second malignancies after modern radiotherapy

WD Newhauser, M Durante - Nature Reviews Cancer, 2011 - nature.com
Recent advances in radiotherapy have enabled the use of different types of particles, such
as protons and heavy ions, as well as refinements to the treatment of tumours with standard …

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

K Metcalfe, S Gershman, HT Lynch, P Ghadirian… - British journal of …, 2011 - nature.com
Purpose: The objective of this study was to estimate the risk of contralateral breast cancer in
BRCA1 and BRCA2 carriers; and measure the extent to which host, family history, and …

Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis

A Valachis, AD Nearchou, P Lind - Breast cancer research and treatment, 2014 - Springer
This meta-analysis investigates the oncological safety of breast-conserving therapy BCT in
BRCA-mutation carriers and the risk for contralateral breast cancer (CBC) compared with …

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

KA Phillips, RL Milne, MA Rookus, MB Daly… - Journal of clinical …, 2013 - ascopubs.org
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …